Professionals and Partners
Go to Professionals and Partners

Professionals and Partners

Our core expertise is the development and manufacturing of high-quality generic and in-licensed medicines with a proven cost-effectiveness ratio.

Individuals and Families
Go to Individuals and Families

Individuals and Families

We believe in improving the life of individuals and families by using the best current research. We use our resources to drive future scientific and manufacturing development for the constant betterment of therapies.


Tchaikapharma High Quality Medicines Inc. is devoted to providing individuals and families with a wide range of affordable contemporary high-quality pharmaceuticals fighting socially significant diseases.

  • March 14, 2018

    Tchaikapharma has won award in the category of solution providers during the Pharm Connect congress which is the most notable meeting of leading pharmaceutical and biotechnology companies for Central Eastern Europe and CIS region. The excellence award was given for the successful incorporation of the latest running and implementation system. This has been a joint […]

  • August 25, 2017

    The Financial Supervision Commission (FSC) registered the shares issued by Tchaikapharma High Quality Medicines Inc. as a result of an increase of the company’s capital with a view to trading on a regulated securities market. This is evident from the regulator’s decisions at the meeting held on the 23rd of August. The equity issue amounts […]

  • July 14, 2017

    The current capital of the pharmaceutical company is BGN 64.3 million. Tchaikapharma High Quality Medicines Inc. announced that following the entry in the Commercial Register the capital of the company was increased by BGN 7.7 million, the announcement came through the BSE-Sofia. The current capital of the pharmaceutical company is BGN 64.3 million, divided into […]

  • June 9, 2017

    The voted dividend for 2016  is 7 700 000. The amount of the capital after the increase is BGN 64 300 000. On June 8, 2017, the Annual General Meeting of Shareholders (GMS) of Tchaikapharma High Quality Medicines Inc. was held with the required quorum. A total of 56,562,089 shares were represented – all with […]

  • April 21, 2017

    The newest addition to Tchaikapharma High Quality Medicines Inc. product list is Ivabenor 5 mg and 7,5 mg film-coated tablets. The cardiological medicinal product contains the active substance ivabradine. Ivabenor is indicated for the treatment of patients with chronic stable angina pectoris and chronic heart failure. ATC code: C01EB 17

  • April 13, 2017

    Tchaikapharma High Quality Medicines Available for All wishes you a Happy Easter!

  • March 24, 2017

    Interview with the production manager at Tchaikapharma’s plant in Plovdiv – Vasil Pavlov.   The requirements for the production of medicinal products resulting from the GMP (good manufacturing practices) enforced around the world approximate (and in many cases exceed) the requirements for operating rooms in hospitals. Medicines are produced in a rigorously monitored environment to […]

  • March 9, 2017

    Bortezomib-Tchaikapharma 3.5 mg powder for solution for injection is Tchaikapharma High Quality Medicines’ newest medicinal product which obtained a Marketing Authorisation by the Bulgarian Drug Agency in the beginning of February 2017. The active substance contained is Bortezomib (as a mannitol boronic ester). The medicinal product is subject to medical prescription. ATC code: L01XX 32

  • February 20, 2017

    Tchaikapharma High Quality Medicines Inc. received another Marketing Authorization by the Bulgarian Drug Agency with which the company updated its list of injectable products. The new oncological drug product is called Pemetrexed-Tchaikapharma 500 mg powder for concentrate for solution for infusion and is used in the treatment of malignant pleural mesothelioma and non-small cell lung […]

  • February 9, 2017

    Bortezomib-Tchaikapharma 3.5 mg powder for solution for injection is Tchaikapharma High Quality Medicines’ newest medicinal product which obtained a Marketing Authorisation by the Bulgarian Drug Agency in the beginning of February 2017. The active substance contained is Bortezomib (as a mannitol boronic ester). The medicinal product is subject to medical prescription. ATC code: L01XX 32

  • February 2, 2017

    Lidocaine-Tchaikapharma 10 mg and 20 mg solution for injection is Tchaikapharma’s newest product which has obtained a Marketing Authorization issued by the Bulgarian Drug Agency. Therapeutic indications: For local anesthesia in surgery, dentistry, urology, cardiology, ophthalmology, otorhinolaryngology and other invasive instrumental investigations. For the treatment of ventricular arrhythmias, including after myocardial infarction and cardiac surgery […]

  • December 23, 2016
  • December 7, 2016

    The outgoing 2016 was a wonderful year of continued progress for Tchaikapharma. It was the first full year since Tchaikapharma was listed as a public company on the Bulgarian Stock Exchange (BSE) in Sofia and after share trading started on 21 May 2015. Actually and based on 3Q16 results followed by very good October and […]

  • November 23, 2016

    The renowned business ranking “300 Business Leaders in Bulgaria” for one more year honoured Tchaikapharma High Quality Medicines Inc. as one of the most profitable and influential companies in Bulgaria. The ranking’s fifth edition prepared by analysts from ICAP Group brings together the most successful companies in the country for the past year 2015, based […]

  • November 15, 2016

    The newest product of Tchaikapharma High Quality Medicines Inc., which BDA gave a marketing authorisation for, is Cilapenem 500 mg/500 mg powder for infusion solution. Each phial contains the following active substances: 530 mg imipenem monohydrate, which is equivalent to 500 mg imipenem anhydrоus, and 532 mg cilastatin sodium, equivalent to 500 mg cilastatin. The drug […]

  • November 7, 2016

    The newest medicinal product placed on the market after having received a marketing authorization from the Bulgarian Drug Agency by the Ministry of Health is the infusion solution Linezolid-Tchaikapharma 2 mg/ml. Its active substance is linezolid, and a packaging contents 300 ml x 5 pcs. or 10 pcs. This medicinal product is used in cases […]

  • September 9, 2016

    The decline in the price of shares of Sopharma during the trading session of Wednesday from 3.24% yesterday and the minimum recovery of only 0.24% led to a new leader among the largest public companies in Bulgaria. Another pharmaceutical company – Tchaikapharma High Quality Medicines Inc. took the forefront place with a market value of […]

  • September 2, 2016

    On the Bulgarian pharmaceutical market the latest addition to constantly growing product list of Tchaikapharma High Quality Medicines Inc.  for the treatment of cardiovascular diseases is offered from today. The product Cardesart-Co x 30 tablets, an international non-proprietary name Candesartan/Hydrochlorothiazide, in concentrations of active ingredients 8 mg/12.5 mg and 16 mg/12,5 mg registered under the […]

  • August 8, 2016

    A total of 8 among the 40 companies included in calculating one of the main indicators of the Bulgarian Stock Exchange – BGBX40, rose more than 10%, and nine companies lose between 13 and 58% of its market valuation, according to a check made by Here are the details for the best and worst […]

  • July 19, 2016

    After successfully completing the third for the company Decentralised Procedure (DCP) Tchaikapharma High Quality Medicines Inc. received Marketing Authorisation for the medicinal product Tamayra 5 mg/5 mg hard capsules and Tamayra 10 mg/5 mg hard capsules, for which Bulgaria is the country of reference This is the first international procedure for Marketing Authorisation of medicinal […]

  • July 14, 2016

    Tchaikapharma High Quality Medicines Inc. was granted Marketing Authorisations for the medicinal products Ibodria 6 mg/6 ml concentrate for solution for infusion and Ibodria 3 mg/3 ml solution for injection in pre-filled syringe. The active substance contained is Ibandronic acid (as ibandronate sodium monohydrate). The medicinal product is indicated for the treatment of osteoporosis in […]

  • June 30, 2016

    The Bulgarian Pharmaceutical Union awarded Tchaikapharma High Quality Medicines Inc. for cardiological medicinal product Amariton in the category “Medicinal Product Subject to Medicinal Prescription – made in Bulgaria” for 2016. The Awards ceremony took place at the Tenth anniversary edition of the Bulgarian Pharmaceutical Days, held from the 24th to 26th of June 2016 at […]

  • June 24, 2016

    By decision of the General Meeting, the company’s capital will be increased by BGN 7 million, which will increase in proportion the number of shares that each shareholder has.   On 23rd June 2016, in the presence of the required quorum, was held the Annual General Meeting (AGM) of shareholders of Tchaikapharma High Quality Medicines […]

  • June 22, 2016

    For the past year the company has reported improved results in its financial performance, introducing new products and entering new markets, as well as advancing in the field of its research and development activities   The Public company Tchaikapharma High Quality Medicines Inc. will hold its Annual General Meeting of Shareholders on 23rd of June […]

  • May 13, 2016

    On 10/05/2016, the BDA successfully completed within the specified period the first decentralised procedure (DCP) for marketing authorisation of medicinal products for which Bulgaria is the Reference Member State (RMS). A team of experts from the BDA assessed the documentation, in connection with the Marketing Authorisation of medicinal products Tamayra 5 mg/5 mg hard capsules […]

  • April 8, 2016

    At the end of the trading day (Thursday 7 April) Tchaikapharma’s shares rose most significantly – they increased by 1.21% and the closing price reached BGN 5.85. This represents another appreciation of the emission, which has risen by 6.06% since the beginning of the year.

  • April 7, 2016

    Dear Colleagues,   Happy Holidays!   Your everyday efforts to improve people’s health and save people’s lives are and have always been worthy of respect! All impediments we face with combined efforts every day to ensure that every Bulgarian has the right of access to the most up-to-date treatment and quality life make us not […]

  • March 23, 2016

    Tchaikapharma High Quality Medicines Inc. successfully launched the trading week. On Monday, the company ranked third in traded volume, having trading volume of nearly BGN 33.4 thousand. The transactions were seven, leading to a rise in the share price by 0.7% up to BGN 5.76. On Tuesday, amid the prevailing unprofitable companies on the Stock […]

  • January 11, 2016

    This year again, employees of Commercial League assumed the role of Santa Claus and delighted the kids from Konstantsa Lyapcheva orphanage in the town of Dolna Banya. More than 20 children were asked to send letters with their Christmas wishes, and the team of Commercial League tried to make them true. Besides the dream gift, […]

  • November 6, 2015

    The National Health Service in the UK discontinues the coverage of 25 cancer drugs Twenty five drugs that each year give a last chance to patients with cancer – including breast, prostate and colon cancer will not be funded by the National Health Service in the UK (NHS), which plans to optimize the costs for […]

  • October 20, 2015

    Tchaikapharma High Quality Medicines Inc. was distinguished among the most profitable and influential companies in Bulgaria for the 2014 business rating “300 Business leaders in Bulgaria”. In this year’s forth edition the business analysts from the ICAP Group rated the most successful companies in the country accordingto the Earnings Before Interest, Taxes, Depreciation, and Amortization […]

  • October 6, 2015

    The participants in the National Round Table on Reforms and Healthcare without Restrictions insist that the government restores the principle “the funding follows the patient” “We do not accept and will not accept in the future the activities of the medical institutions to limit and thereby to put bounds on the rights of patients to […]

  • The specialized hospitals of the Bulgarian Cardiac Institute in Varna, Veliko Tarnovo, Shumen and Yambol mark the World Heart Day with an appeal for prevention and free consultations Every year on the 29th of September  the world celebrates the International Heart Day. In connection with this the experts reminded us that according to the “black […]

  • October 2, 2015

    For the first time clinical trials will be conducted to check if a drug prolonged life, said magazine  Sciences et Avenir. The medicine in question is metformin, which is often administered to patients affected by diabetes type 2. In 2008, the study of Russian scientists showed that it prolonged the lives of mice, probably by […]

  • According to Minister Moskov, when one has a facility in the big city where people have assets, one has to take responsibility for the system as well. According to the guild, the solution is to permit subsidiaries Administratively forcible is the method imposed by the state that out of the 4 pharmacies, which an owner […]

  • Doctors specializing in Medicine will have a right to a contract with the NHIF was decided by the MPs yesterday, when they accepted the amendments to the Law on Medical Institutions. This way they made the promise of the Health Minister Petar Moskov, which he made to the doctors in the campaign “Young Medic”, become […]

  • The Health Insurance Fund will finance hospitals only according to the needs of the population The Health Insurance Fund will not finance all newfound hospitals and will base its decisions on the National Health Card, which will have an obligatory nature. It will list the needs of the regional population. This was the bottom-line decision […]

  • September 1, 2015

    For the first time the Republic of Bulgaria, as a Member State of the EU, will be the reference country in the decentralized procedure (DCP) for Marketing Authorisation for a medicinal products with applicant Tchaikapharma High Quality Medicines Inc., Bulgaria. The concerned parties in the procedure are Austria, Greece, Portugal, Romania, Slovakia and the Czech […]

  • July 14, 2015

    Bulgarian Drug Agency issued a new Marketing Authorisation to Tchaikapharma High Quality Medicines Inc. for the medicinal product for treatment of diabetes mellitus Aroba 100 mg tablets. Aroba contains the active substance acarbose, and belongs to the group of medicines called alpha-glucosidase inhibitors. It is used as supplement treatment concomitantly with diet in patients with […]

  • July 13, 2015

    The Guardian wrote that the Scientists had found that two licensed drugs stopped the degeneration of the brain in mice. The discovery gives hope of success in the search for drugs for the therapy of Alzheimer’s disease. The results, presented at the annual conference of scientists researching Alzheimer’s disease, were defined as “promising” because the […]

  • Prof. Marita Eisenmann predicted that after 10 years the fat grifting method will completely replace breast implants. Three women after mammectomy due to breast cancer undergo reconstructive surgery today in Sofia First Gynecological Hospital “St. Sofia” by a Bulgarian team of specialists, led by the world-renowned plastic surgeon Prof. Marita Eisenmann – Klein. This was […]

  • There are reported cases of serious, sometimes life-threatening cases of diabetic ketoacidosis in patients with type 2 diabetes treated with SGLT2-inhibitors. This is reported by the manufacturers after consultation with the European Medicines Agency (EMA) and the Bulgarian Drug Agency (BDA). In a number of these reports the clinical presentation of the condition is atypical, […]

  • During the past 2014 the NHIF allocated 72 million for rare medicines The innovations are crucial for achieving better treatment, but they are very expensive. Good examples of this are the so called “orphan drugs”, which treat rare diseases. Treatment of a patient for a year could exceed millions. Because of that the access is […]

  • A new front in the National Assembly against the reduced requirements for managers was formed. The Health Minister Petar Moskov has proposed a liberalization of the requirements for managers in the Medical Institutions Act and virtually anyone who has a master degree in economics may become head of a hospital. This formed a new front […]

  • The results of a retrospective study published in the Journal of the American College of Cardiology show that the patients with critical limb ischemia who took statins had a significantly lower incidence of major adverse cardiac events (MACE) and amputations. The register of patients with peripheral arterial disease (PAD) from 2006 to 2012 was analized […]

  • July 2, 2015

    Scientists from the Edinburgh University announced that they had found the mechanism that allows breast cancer to spread to the lungs, wrote The Guardian. The team of scientists found that blocking it in mice with the disease reduced the number of secondary tumors in the lungs. The researchers hope that their achievement would lead to […]

  • The party Patriotic Front (PF) would propose a change in the Hospitals Act with which to establish a Register of Medical Errors. This was announced by MP Dr. Sultanka Petrova. Building the system had been discussed for years, leading specialists and the Doctors’ Union had kept demanding that from time to time, but it hadn’t […]

  • The Supervisory Board of the National Health Insurance Fund is expecting from the BMA proposals for solving the problem of clinical pathways overspending. This became clear from the words of the member of the Supervisory Board Dr. Evgeni Tasovski. “We look at where the pain is, and this is the spot that is to be […]

  • Many people called their personal doctors to enroll for a checkup after the Health Minister Dr. Petar Moskov said that if routine preventive checkups were skipped, there should be a higher health insurance, announced the GPs. Even now there is a fine of BGN 50 for skipping the annual checkup provided for in the Health […]

  • Insulin resistance and beta-cell dysfunction are the two key pathophysiological disorders of diabetes mellitus type 2 (DM T2). The liver, muscle and the adipose tissue are resistant to insulin action. The basal hepatic glucose output is increased, despite the high plasma insulin levels, indicating the presence of hepatic insulin resistance. Increased glucose production by the […]